Literature DB >> 25378237

Functional characterization and classification of frequent low-density lipoprotein receptor variants.

Aitor Etxebarria1, Asier Benito-Vicente, Lourdes Palacios, Marianne Stef, Ana Cenarro, Fernando Civeira, Helena Ostolaza, Cesar Martin.   

Abstract

Familial hypercholesterolemia (FH) is an autosomal-dominant disorder mostly caused by mutations in the low-density lipoprotein receptor (LDLR) gene leading to increased risk for premature cardiovascular diseases. According to functional studies, LDLR mutations may be classified into five classes. The main objective of this study was to characterize seven LDLR variants previously detected in FH patients. Analysis by flow cytometry and confocal microscopy of LDLR activity demonstrate that all the studied variants are pathogenic. Among the mutations located in β-propeller, p.Trp577Gly and p.Ile624del were classified as class 2, whereas p.Arg416Trp and p.Thr454Asn as class 5. p.Phe800Glyfs*129 (located in the cytoplasmic domain), p.Cys155Tyr (located in the binding domain), and p.Asn825Lys (inside FxNPxY motif) were classified as class 2, 3, and 4, respectively. The results also show that LDLR activity of these class 4 and 5 variants is not completely abolished, showing a milder phenotype. We have also determined that statin response is more efficient lowering total cholesterol in heterozygous patients carrying p.Ile624del (class 2) compared with p.Arg416Trp and p.Thr454Asn (class 5) variants. In conclusion, these findings emphasize the importance of characterizing LDLR pathogenic variants to provide an indisputable FH diagnosis and to gain insight into the statin response depending on the LDLR class mutation.
© 2014 WILEY PERIODICALS, INC.

Entities:  

Keywords:  LDRL; familial hypercholesterolemia; mutation class defect; mutations; statins

Mesh:

Substances:

Year:  2014        PMID: 25378237     DOI: 10.1002/humu.22721

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  14 in total

1.  The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.

Authors:  Delia Susan-Resiga; Emmanuelle Girard; Robert Scott Kiss; Rachid Essalmani; Josée Hamelin; Marie-Claude Asselin; Zuhier Awan; Chutikarn Butkinaree; Alexandre Fleury; Armand Soldera; Yves L Dory; Alexis Baass; Nabil G Seidah
Journal:  J Biol Chem       Date:  2016-12-20       Impact factor: 5.157

2.  The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia.

Authors:  Asier Benito-Vicente; Ana Catarina Alves; Aitor Etxebarria; Ana Medeiros Medeiros; Cesar Martin; Mafalda Bourbon
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

3.  The UCL low-density lipoprotein receptor gene variant database: pathogenicity update.

Authors:  Sarah Leigh; Marta Futema; Ros Whittall; Alison Taylor-Beadling; Maggie Williams; Johan T den Dunnen; Steve E Humphries
Journal:  J Med Genet       Date:  2016-11-07       Impact factor: 6.318

4.  A Rare Missense Mutation and a Polymorphism with High Frequency in LDLR Gene among Iranian Patients with Familial Hypercholesterolemia.

Authors:  Masoud Tajamolian; Parisa Kolahdouz; Parvaneh Nikpour; Seyed Khalil Forouzannia; Mohammad Hasan Sheikhha; Ehsan Farashahi Yazd
Journal:  Adv Biomed Res       Date:  2018-02-21

5.  PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.

Authors:  Elise F Villard; Aurélie Thedrez; Jorg Blankenstein; Mikaël Croyal; Thi-Thu-Trang Tran; Bruno Poirier; Jean-Christophe Le Bail; Stéphane Illiano; Estelle Nobécourt; Michel Krempf; Dirk J Blom; A David Marais; Philip Janiak; Anthony J Muslin; Etienne Guillot; Gilles Lambert
Journal:  JACC Basic Transl Sci       Date:  2016-10

Review 6.  Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

7.  p.(Asp47Asn) and p.(Thr62Met): non deleterious LDL receptor missense variants functionally characterized in vitro.

Authors:  A Benito-Vicente; H Siddiqi; K B Uribe; S Jebari; U Galicia-Garcia; A Larrea-Sebal; M Stef; H Ostolaza; L Palacios; C Martin
Journal:  Sci Rep       Date:  2018-11-09       Impact factor: 4.379

8.  Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.

Authors:  Poulabi Banerjee; Kuo-Chen Chan; Michel Tarabocchia; Asier Benito-Vicente; Ana C Alves; Kepa B Uribe; Mafalda Bourbon; Paul J Skiba; Robert Pordy; Daniel A Gipe; Daniel Gaudet; Cesar Martin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-03       Impact factor: 8.311

9.  Replacement of cysteine at position 46 in the first cysteine-rich repeat of the LDL receptor impairs apolipoprotein recognition.

Authors:  A Benito-Vicente; K B Uribe; H Siddiqi; S Jebari; U Galicia-Garcia; A Larrea-Sebal; A Cenarro; M Stef; H Ostolaza; F Civeira; L Palacios; C Martin
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

Review 10.  Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-11-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.